Similarly, the complete tumor remissions on ICI-based therapy in mCRPC patients who have MSI/MMR deficiency suggest that the initial molecular tumor profile for screening DDR defects should also include the aberrations of the MMR pathway. The gene discussed is MRC1; the disease is mismatch repair cancer syndrome 1.